Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 2017—Alere announced that its Alere Reader, a diagnostic platform with objective result interpretation and connectivity capabilities that can be used to evaluate a variety of lateral flow immunoassay formats and that can be used in point-of-care and laboratory settings, received FDA 510(k) clearance.
June 2017—ArcherDx and precision medicine company HeliTec (Shenzhen, China) announced a strategic partnership to advance NGS-based cancer diagnostic development in China. The partnership will entail co-developing and cross-licensing NGS-based technologies with the goal of registering oncology diagnostic kits with the Chinese Food and Drug Administration.
June 2017—MedTest announced the commercial launch of urine drugs of abuse screening reagents on the Mindray BA-800M chemistry analyzer for use in clinical laboratories in the United States.
June 2017—Horiba has developed two new hematology systems, the Yumizen H1500 and the Yumizen H2500. The CE-marked analyzers offer a throughput of 120 tests per hour for complete blood count, including differential and nucleated red blood cells, and are equipped with a three-dimensional count capable of combining the measurements of cellular complexity, volume, and distribution for each of the leukocyte subpopulations.
June 2017—Immunexpress received FDA 510(k) clearance for the use of SeptiCyte Lab as an aid in differentiating infection-positive (sepsis) from infection-negative (SIRS) systemic inflammation in critically ill patients on their first day of ICU admission. It is the first RNA-based clinical diagnostic tool, direct from whole blood, to aid medical providers in the early identification of infection in suspected sepsis patients, according to a company statement.
June 2017—The U.S. Department of Health and Human Services announced that Siemens Healthineers has been awarded $8.9 million by the Office of the Assistant Secretary for Preparedness and Response’s Biomedical Advanced Research and Development Authority to advance the development of a Zika assay for use on the company’s Advia Centaur XPT, Advia Centaur XP, and Advia Centaur CP immunoassay systems for the clinical laboratory.
June 2017—EntroGen announced CE-IVD marking of its Colorectal Cancer Panel (CRC), Thyroid Cancer Mutation Analysis kit (THDNA), and Thyroid Cancer Fusion Gene Detection kit (THRNA).
June 2017—The Olympus CX43 and CX33 microscopes are designed to keep users comfortable during long periods of use, maximizing work efficiency. Features of the microscopes that minimize user fatigue include a stage that is 70 mm lower than the previous model, resulting in a large working space under the eyepieces, which makes it easier to check or swap samples with just one hand; a stage knob and co-axial focus knobs that are designed lower to the microscope base so users can reach the controls while their forearms remain resting on the desk; and a low-positioned revolving nosepiece that accommodates up to five objectives and enables users to quickly change magnification with minimal arm movement.
June 2017—Quest Diagnostics and PeaceHealth have formed a two-part arrangement to enhance the delivery of laboratory services to communities in Oregon, Washington, and Alaska.
June 2017—Oxford Gene Technology has expanded its SureSeq myPanel NGS Custom Cancer Panel content. The expanded content covers more than 70 genes optimized for hematology and solid tumors including breast, colorectal, lung, ovarian and prostate cancer, glioma, melanoma, sarcoma, leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome.
